These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25479724)

  • 1. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
    Feng G; Chang-Qing Z; Yi-Min C; Xiao-Lin L
    Int Immunopharmacol; 2015 Jan; 24(1):7-13. PubMed ID: 25479724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats.
    Suen PK; He YX; Chow DH; Huang L; Li C; Ke HZ; Ominsky MS; Qin L
    J Orthop Res; 2014 Aug; 32(8):997-1005. PubMed ID: 24782158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
    Ominsky MS; Li C; Li X; Tan HL; Lee E; Barrero M; Asuncion FJ; Dwyer D; Han CY; Vlasseros F; Samadfam R; Jolette J; Smith SY; Stolina M; Lacey DL; Simonet WS; Paszty C; Li G; Ke HZ
    J Bone Miner Res; 2011 May; 26(5):1012-21. PubMed ID: 21542004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model.
    Morse A; McDonald MM; Schindeler A; Peacock L; Mikulec K; Cheng TL; Liu M; Ke HZ; Little DG
    Calcif Tissue Int; 2017 Aug; 101(2):217-228. PubMed ID: 28391431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model.
    Tinsley BA; Dukas A; Pensak MJ; Adams DJ; Tang AH; Ominsky MS; Ke HZ; Lieberman JR
    J Bone Joint Surg Am; 2015 Nov; 97(22):1852-9. PubMed ID: 26582615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model.
    Virk MS; Alaee F; Tang H; Ominsky MS; Ke HZ; Lieberman JR
    J Bone Joint Surg Am; 2013 Apr; 95(8):694-701. PubMed ID: 23595067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
    Liu Y; Rui Y; Cheng TY; Huang S; Xu L; Meng F; Lee WY; Zhang T; Li N; Li C; Ke H; Li G
    Calcif Tissue Int; 2016 Mar; 98(3):263-74. PubMed ID: 26603303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model.
    Alaee F; Virk MS; Tang H; Sugiyama O; Adams DJ; Stolina M; Dwyer D; Ominsky MS; Ke HZ; Lieberman JR
    J Orthop Res; 2014 Feb; 32(2):197-203. PubMed ID: 24600701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent effects of sclerostin antibody on a mouse fracture healing model.
    Cui L; Cheng H; Song C; Li C; Simonet WS; Ke HZ; Li G
    J Musculoskelet Neuronal Interact; 2013 Jun; 13(2):178-84. PubMed ID: 23728104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis.
    McDonald MM; Morse A; Birke O; Yu NYC; Mikulec K; Peacock L; Schindeler A; Liu M; Ke HZ; Little DG
    J Orthop Res; 2018 Apr; 36(4):1106-1113. PubMed ID: 28884841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.
    Roudier M; Li X; Niu QT; Pacheco E; Pretorius JK; Graham K; Yoon BR; Gong J; Warmington K; Ke HZ; Black RA; Hulme J; Babij P
    Arthritis Rheum; 2013 Mar; 65(3):721-31. PubMed ID: 23233270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin antibody stimulates bone regeneration after experimental periodontitis.
    Taut AD; Jin Q; Chung JH; Galindo-Moreno P; Yi ES; Sugai JV; Ke HZ; Liu M; Giannobile WV
    J Bone Miner Res; 2013 Nov; 28(11):2347-56. PubMed ID: 23712325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Root bark of Sambucus Williamsii Hance promotes rat femoral fracture healing by the BMP-2/Runx2 signaling pathway.
    Yang B; Lin X; Tan J; She X; Liu Y; Kuang H
    J Ethnopharmacol; 2016 Sep; 191():107-114. PubMed ID: 27178636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.
    Hamann C; Rauner M; Höhna Y; Bernhardt R; Mettelsiefen J; Goettsch C; Günther KP; Stolina M; Han CY; Asuncion FJ; Ominsky MS; Hofbauer LC
    J Bone Miner Res; 2013 Mar; 28(3):627-38. PubMed ID: 23109114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect.
    Jawad MU; Fritton KE; Ma T; Ren PG; Goodman SB; Ke HZ; Babij P; Genovese MC
    J Orthop Res; 2013 Jan; 31(1):155-63. PubMed ID: 22887736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.